vs

Side-by-side financial comparison of California BanCorp \ CA (BCAL) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $45.9M, roughly 1.5× California BanCorp \ CA). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 35.8%, a 348.3% gap on every dollar of revenue. On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs 0.8%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 44.7%).

Pacific Premier Bancorp, Inc. is an American bank holding company under the Bank Holding Company Act of 1956 headquartered in Irvine, California, US. Its principal business focuses on Pacific Premier Bank, which offers a range of financial services to individuals, businesses, and professionals. The bank operates numerous branches in California, Arizona, Nevada, and Washington.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

BCAL vs RIGL — Head-to-Head

Bigger by revenue
RIGL
RIGL
1.5× larger
RIGL
$69.8M
$45.9M
BCAL
Growing faster (revenue YoY)
RIGL
RIGL
+20.4% gap
RIGL
21.2%
0.8%
BCAL
Higher net margin
RIGL
RIGL
348.3% more per $
RIGL
384.0%
35.8%
BCAL
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
44.7%
BCAL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCAL
BCAL
RIGL
RIGL
Revenue
$45.9M
$69.8M
Net Profit
$16.4M
$268.1M
Gross Margin
91.5%
Operating Margin
48.8%
33.2%
Net Margin
35.8%
384.0%
Revenue YoY
0.8%
21.2%
Net Profit YoY
-2.1%
1769.2%
EPS (diluted)
$0.50
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCAL
BCAL
RIGL
RIGL
Q4 25
$45.9M
$69.8M
Q3 25
$45.2M
$69.5M
Q2 25
$44.3M
$101.7M
Q1 25
$44.8M
$53.3M
Q4 24
$45.5M
$57.6M
Q3 24
$38.1M
$55.3M
Q2 24
$22.2M
$36.8M
Q1 24
$21.9M
$29.5M
Net Profit
BCAL
BCAL
RIGL
RIGL
Q4 25
$16.4M
$268.1M
Q3 25
$15.7M
$27.9M
Q2 25
$14.1M
$59.6M
Q1 25
$16.9M
$11.4M
Q4 24
$16.8M
$14.3M
Q3 24
$-16.5M
$12.4M
Q2 24
$190.0K
$-1.0M
Q1 24
$4.9M
$-8.2M
Gross Margin
BCAL
BCAL
RIGL
RIGL
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Q1 24
93.1%
Operating Margin
BCAL
BCAL
RIGL
RIGL
Q4 25
48.8%
33.2%
Q3 25
48.3%
40.9%
Q2 25
45.3%
60.1%
Q1 25
52.8%
23.9%
Q4 24
52.2%
28.9%
Q3 24
-59.1%
25.4%
Q2 24
1.3%
1.2%
Q1 24
33.1%
-23.6%
Net Margin
BCAL
BCAL
RIGL
RIGL
Q4 25
35.8%
384.0%
Q3 25
34.7%
40.2%
Q2 25
31.8%
58.6%
Q1 25
37.6%
21.5%
Q4 24
37.7%
24.9%
Q3 24
-43.2%
22.5%
Q2 24
0.9%
-2.8%
Q1 24
22.5%
-27.9%
EPS (diluted)
BCAL
BCAL
RIGL
RIGL
Q4 25
$0.50
$14.11
Q3 25
$0.48
$1.46
Q2 25
$0.43
$3.28
Q1 25
$0.52
$0.63
Q4 24
$0.54
$0.82
Q3 24
$-0.59
$0.70
Q2 24
$0.01
$-0.06
Q1 24
$0.26
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCAL
BCAL
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$399.9M
$155.0M
Total DebtLower is stronger
$33.8M
$52.5M
Stockholders' EquityBook value
$576.6M
$391.5M
Total Assets
$4.0B
$513.6M
Debt / EquityLower = less leverage
0.06×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCAL
BCAL
RIGL
RIGL
Q4 25
$399.9M
$155.0M
Q3 25
$559.2M
$137.1M
Q2 25
$430.1M
$108.4M
Q1 25
$439.2M
$77.1M
Q4 24
$388.2M
$77.3M
Q3 24
$614.4M
$61.1M
Q2 24
$104.7M
$49.1M
Q1 24
$86.5M
$49.5M
Total Debt
BCAL
BCAL
RIGL
RIGL
Q4 25
$33.8M
$52.5M
Q3 25
$33.4M
$60.0M
Q2 25
$52.9M
$60.0M
Q1 25
$70.3M
$60.0M
Q4 24
$69.7M
$60.0M
Q3 24
$69.1M
$60.0M
Q2 24
$42.9M
$60.0M
Q1 24
$44.9M
$60.0M
Stockholders' Equity
BCAL
BCAL
RIGL
RIGL
Q4 25
$576.6M
$391.5M
Q3 25
$564.7M
$117.6M
Q2 25
$547.6M
$81.9M
Q1 25
$531.4M
$18.6M
Q4 24
$511.8M
$3.3M
Q3 24
$498.1M
$-14.6M
Q2 24
$293.2M
$-29.9M
Q1 24
$292.5M
$-31.7M
Total Assets
BCAL
BCAL
RIGL
RIGL
Q4 25
$4.0B
$513.6M
Q3 25
$4.1B
$242.5M
Q2 25
$4.0B
$206.7M
Q1 25
$4.0B
$176.0M
Q4 24
$4.0B
$164.0M
Q3 24
$4.4B
$139.4M
Q2 24
$2.3B
$128.4M
Q1 24
$2.3B
$126.5M
Debt / Equity
BCAL
BCAL
RIGL
RIGL
Q4 25
0.06×
0.13×
Q3 25
0.06×
0.51×
Q2 25
0.10×
0.73×
Q1 25
0.13×
3.23×
Q4 24
0.14×
18.25×
Q3 24
0.14×
Q2 24
0.15×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCAL
BCAL
RIGL
RIGL
Operating Cash FlowLast quarter
$57.3M
$22.0M
Free Cash FlowOCF − Capex
$56.9M
FCF MarginFCF / Revenue
124.1%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
3.49×
0.08×
TTM Free Cash FlowTrailing 4 quarters
$93.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCAL
BCAL
RIGL
RIGL
Q4 25
$57.3M
$22.0M
Q3 25
$16.0M
$24.0M
Q2 25
$13.4M
$30.5M
Q1 25
$7.0M
$-893.0K
Q4 24
$50.3M
$14.5M
Q3 24
$18.3M
$21.7M
Q2 24
$309.0K
$302.0K
Q1 24
$8.1M
$-5.0M
Free Cash Flow
BCAL
BCAL
RIGL
RIGL
Q4 25
$56.9M
Q3 25
$15.9M
Q2 25
$13.4M
Q1 25
$6.9M
Q4 24
$49.7M
Q3 24
$18.1M
Q2 24
$171.0K
Q1 24
$8.0M
FCF Margin
BCAL
BCAL
RIGL
RIGL
Q4 25
124.1%
Q3 25
35.1%
Q2 25
30.2%
Q1 25
15.3%
Q4 24
109.2%
Q3 24
47.5%
Q2 24
0.8%
Q1 24
36.4%
Capex Intensity
BCAL
BCAL
RIGL
RIGL
Q4 25
0.8%
Q3 25
0.2%
Q2 25
0.1%
Q1 25
0.2%
Q4 24
1.2%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.4%
Cash Conversion
BCAL
BCAL
RIGL
RIGL
Q4 25
3.49×
0.08×
Q3 25
1.02×
0.86×
Q2 25
0.95×
0.51×
Q1 25
0.41×
-0.08×
Q4 24
3.00×
1.01×
Q3 24
1.75×
Q2 24
1.63×
Q1 24
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons